Stock info Pierrel | Filter  Basic-Info

Pierrel

The past year gave good returns for Pierrel investors

The period between December 2015 and December 2016 was a loss-making period for the investors in Pierrel. The stock lost around 69 percent. Over the period 2011-2016 the stock lost a massive -75,92 percent. Pierrel's revenues between 2011 and 2015 were very volatile and moved between 47,25 million euros and 32,51 million euros. Pierrel's net results between 2011 and 2015 were far from constant and moved between -7,73 million euros and -18,12 million euros.

The company's head quarter is located in Cant�. Pierrel's core business is the pharmaceutical sector. Luigi Visani is the company' CEO. Marco Radice leads the company as CFO. The past 10 years the (international) industry gained at around 75 percent. Measured since 2011 the sector is 147 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 75 percent.

The Italian company didn't pay out any dividends (in the past 5 years).

Pierrel financed with a quite low debt position

As per the end of 2015 the Italian company's balance sheet equaled 63,46 million euros. The total debt was around 78,67 million euros. This is 123,97 percent of the total balance sheet. The Italian company's price/earnings-ratio was -5. So the market valued the stock at -5 times the 2015' earnings per share. Based on it's price/earnings-ratio and dividend yield the Italian stock can be seen as a value stock.

At the end of 2015 the pharmaceutical company's market size (her number of outstanding share times the stock price) equaled around 27,05 million euros. At the end of 2015 the Italian company had around 49,18 million stocks listed.

On this page you can find all Pierrel's financial reports. More information about Pierrel can be found it's website. .